| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33084 | |||
| IHC-Prediluted | NBP2-44524 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB500-180SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-81445-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56694SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-83940-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-526-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33074 | |||
| IHC-Prediluted | NBP2-44976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-88861-25ul | |||
![Immunohistochemistry-Paraffin: p21/CIP1/CDKN1A Antibody (WA-1) [NBP2-29463] - Formalin-fixed, paraffin-embedded human bladder carcinoma stained with p21 Monoclonal Antibody (WA-1).](http://images.novusbio.com/fullsize/p21-CIP1-CDKN1A-Antibody-WA-1-Immunohistochemistry-Paraffin-NBP2-29463-img0001.jpg "Immunohistochemistry-Paraffin: p21/CIP1/CDKN1A Antibody (WA-1) [NBP2-29463] - Formalin-fixed, paraffin-embedded human bladder carcinoma stained with p21 Monoclonal Antibody (WA-1).")
![Western Blot: Kif2a Antibody [NB500-180] - Western blot shows lysates of HEK293T human embryonic kidney parental cell line and Kif2a knockout (KO) HEK293T cell line. PVDF membrane was probed with 1:10000 of Rabbit Anti-Human Kif2a Polyclonal Antibody (Catalog # NB500-180) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for Kif2a at approximately 100 kDa (as indicated) in the parental HEK293T cell line, but is not detectable in the knockout HEK293T cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/Kif2a-Antibody-Knockout-Validated-NB500-180-img0007.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Kif2a Antibody [NB500-180] - Western blot shows lysates of HEK293T human embryonic kidney parental cell line and Kif2a knockout (KO) HEK293T cell line. PVDF membrane was probed with 1:10000 of Rabbit Anti-Human Kif2a Polyclonal Antibody (Catalog # NB500-180) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for Kif2a at approximately 100 kDa (as indicated) in the parental HEK293T cell line, but is not detectable in the knockout HEK293T cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: Kif2a Antibody [NB500-180] - Analysis of Kif2a in Hela, 3T3 and PC12 lysate.](http://images.novusbio.com/fullsize/Kif2a-Antibody-Western-Blot-NB500-180-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: Kif2a Antibody [NB500-180] - Kif2a antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/Kif2a-Antibody-Immunocytochemistry-Immunofluorescence-NB500-180-img0005.jpg)
![Simple Western: Kif2a Antibody [NB500-180] - Lane view shows a specific band for Kif2a in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Kif2a-Antibody-Simple-Western-NB500-180-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: CEP164 Antibody [NBP1-81445] - Fetuin-A inhibits ciliogenesis. Primary cilia were examined in the absence (CTL) or presence of fetuin-A (FA) by immunostaining with antibodies against acetylated tubulin (Ace-tub), Cep164, IFT88, or Arl13b. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/20/20/5207), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-81445-img0014.jpg "Immunocytochemistry/Immunofluorescence: CEP164 Antibody [NBP1-81445] - Fetuin-A inhibits ciliogenesis. Primary cilia were examined in the absence (CTL) or presence of fetuin-A (FA) by immunostaining with antibodies against acetylated tubulin (Ace-tub), Cep164, IFT88, or Arl13b. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/20/20/5207), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: CEP164 Antibody [NBP1-81445] - Staining of human fallopian tube shows strong positivity in cilia in glandular cells.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunohistochemistry-Paraffin-NBP1-81445-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: CEP164 Antibody [NBP1-81445] - Staining of human cell line U-2 OS shows localization to centrosome. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-81445-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CEP164 Antibody [NBP1-81445] - CEP295 overexpression induces extra-long microtubule-based filaments with low efficiency. Schematics on right of D indicate centrioles (black rectangles) and positions of CEP164 (red squares). MC, mother centriole; DC, daughter centriole. Image collected and cropped by CiteAb from the following publication (//jcs.biologists.org/lookup/doi/10.1242/jcs.186338), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-81445-img0013.jpg)
![Immunohistochemistry-Paraffin: CEP164 Antibody [NBP1-81445] - Staining of human skeletal muscle shows no positivity in myocytes as expected.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunohistochemistry-Paraffin-NBP1-81445-img0008.jpg)
![Immunohistochemistry-Paraffin: CEP164 Antibody [NBP1-81445] - Staining of human bronchus shows moderate to strong positivity in cilia in respiratory epithelial cells.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunohistochemistry-Paraffin-NBP1-81445-img0009.jpg)
![Immunohistochemistry-Paraffin: CEP164 Antibody [NBP1-81445] - Staining of human nasopharynx shows strong positivity in cilia in respiratory epithelial cells.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunohistochemistry-Paraffin-NBP1-81445-img0010.jpg)
![Immunohistochemistry-Paraffin: CEP164 Antibody [NBP1-81445] - Staining of human endometrium shows strong positivity in cilia in glandular cells.](http://images.novusbio.com/fullsize/CEP164-Antibody-Immunohistochemistry-Paraffin-NBP1-81445-img0011.jpg)
![Immunocytochemistry/ Immunofluorescence: CEP164 Antibody [NBP1-81445] - Super-resolution (3D-SIM) microscopic analysis of centriolar distal-end proteins. (a) RPE1 cells were synchronized at G2 phase & immunostained with the indicated antibodies. Lower panels show fluorescence profile plots. Representative images of more than ten cells are presented in (a). ND: nascent daughter centriole, M: mother centriole. (b) The diameters of C2CD3, Talpid3, CEP120, & CEP164 protein spots (n = 30/each). Cumulative data from three independent experiments are shown. ***P < 0.001. (c,d) 3D-SIM analysis of the spatial localizations of C2CD3 (c), Talpid3 (d) & CEP120 (c,d) at the distal ends of centrioles. RPE1 cells were synchronized at G2 phase & immunostained with the indicated antibodies. Scale bar, 100 nm in (a,c,d). (e) Schematic illustration of the spatial localizations of C2CD3, Talpid3, CEP120, & CP110 at the distal ends of centrioles. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30988386), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-81445_rabbit-polyclonal-cep164-antibody-310202416113546.jpg)
![Immunocytochemistry/ Immunofluorescence: CEP164 Antibody [NBP1-81445] - Depletion of RTTN produces shorter centrioles. a, b U2OS cells were treated with siControl or siRTTN as shown in a, & analyzed by confocal fluorescence microscopy using the indicated antibodies. cHistogram illustrating the distance between the CEP162-positive dots associated with a given pair of orthogonally oriented centrioles. Error bars represent the mean ± s.d.; ***P < 0.001 (two-tailed t-test). d, f PLK4-myc doxycycline (Dox) inducible cells were treated with siControl or siRTTN as shown in a, & then analyzed by confocal fluorescence microscopy using the indicated antibodies d, or by electron microscopy f. e, gHistogram illustrating the length of procentrioles in PLK4-myc-inducible cells, as analyzed by confocal microscopy e or electron microscopy g. Error bars represent the mean ± s.d.; ***P < 0.001 (two-tailed t-test). The procentriole length in b/c was measured as the distance between two CEP162 dots as described by Azimzadeh et al.17 The procentriole length in d/e was measured as the distance between the fluorescent peak intensity of SAS-6 (red) & CEP162 (green) in siControl & siRTTN-treated cells. Scale bar, 5 μm in b & d; Scale bar, 200 nm in f Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-00305-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-81445_rabbit-polyclonal-cep164-antibody-310202416121961.jpg)
![Immunocytochemistry/ Immunofluorescence: CEP164 Antibody [NBP1-81445] - CPAP-E1235V mutation impaired the recruitment of centriole elongation proteins onto the centrioles. Cells were synchronized in the early S phase by treatment with aphidicolin (2 μg/ml) for 24 h. They were then fixed immediately with methanol (S phase centrioles) or released into fresh culture medium without aphidicolin for another 16 h (G2 phase centrioles). CPAP-WT or mutant cells in the S phase or G2 phase were immunostained with antibodies against the following centriolar proteins. (A) STIL, n = 42 for CPAP-WT; n = 25 for CPAP-E1235V#1; n = 34 for CPAP-E1235V#2. (B) CEP120, n = 50 for CPAP-WT; n = 42 for CPAP-E1235V#1; n = 48 for CPAP-E1235V#2. (C) CENTROBIN, n = 40 for all groups. (D) CEP295, n = 40 for all groups. (E) POC5, n = 42 for CPAP-WT; n = 40 for CPAP-E1235V#1; n = 40 for CPAP-E1235V#2. (F) POC1B, n = 40 for all groups. (G) CEP164, n = 88 for CPAP-WT; n = 74 for CPAP-E1235V#1; n = 38 for CPAP-E1235V#2. All data are presented as mean ±SEM from a pool of n cells from three independent experiments. n.s: not significant; **p < 0.01; ***p < 0.001. Scale bar: 5 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35309908), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-81445_rabbit-polyclonal-cep164-antibody-31020241613623.jpg)
![Immunocytochemistry/ Immunofluorescence: CEP164 Antibody [NBP1-81445] - Depletion of RTTN produces shorter centrioles. a, b U2OS cells were treated with siControl or siRTTN as shown in a, & analyzed by confocal fluorescence microscopy using the indicated antibodies. cHistogram illustrating the distance between the CEP162-positive dots associated with a given pair of orthogonally oriented centrioles. Error bars represent the mean ± s.d.; ***P < 0.001 (two-tailed t-test). d, f PLK4-myc doxycycline (Dox) inducible cells were treated with siControl or siRTTN as shown in a, & then analyzed by confocal fluorescence microscopy using the indicated antibodies d, or by electron microscopy f. e, gHistogram illustrating the length of procentrioles in PLK4-myc-inducible cells, as analyzed by confocal microscopy e or electron microscopy g. Error bars represent the mean ± s.d.; ***P < 0.001 (two-tailed t-test). The procentriole length in b/c was measured as the distance between two CEP162 dots as described by Azimzadeh et al.17 The procentriole length in d/e was measured as the distance between the fluorescent peak intensity of SAS-6 (red) & CEP162 (green) in siControl & siRTTN-treated cells. Scale bar, 5 μm in b & d; Scale bar, 200 nm in f Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-00305-0), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-81445_rabbit-polyclonal-cep164-antibody-310202416114711.jpg)
![Immunocytochemistry/Immunofluorescence: beta-III Tubulin Antibody (TU-20) [NB600-1018] - Merged image of co-staining with anti-beta-tubulin (TU-06; green) Superposition of red and green colours provided yellow staining. Nuclei were stained with DNA-binding dye (blue).](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-TU-20-Immunocytochemistry-Immunofluorescence-NB600-1018-img0007.jpg "Immunocytochemistry/Immunofluorescence: beta-III Tubulin Antibody (TU-20) [NB600-1018] - Merged image of co-staining with anti-beta-tubulin (TU-06; green) Superposition of red and green colours provided yellow staining. Nuclei were stained with DNA-binding dye (blue).")
![Flow Cytometry: beta-III Tubulin Antibody (TU-20) [NB600-1018] - An intracellular stain was performed on SH-SY5Y cells with beta-III Tubulin (TU-20) antibody NB600-1018PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-TU-20-Flow-Cytometry-NB600-1018-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: beta-III Tubulin Antibody (TU-20) [NB600-1018] - Staining of P-19 mouse embryonal carcinoma cell line stimulated to neuronal differentiation by retinoic acid. 2A - Microtubules decorated with neuron-specific anti-betaIII-tubulin (TU-20; red).](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-TU-20-Immunocytochemistry-Immunofluorescence-NB600-1018-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: beta-III Tubulin Antibody (TU-20) [NB600-1018] - Staining of Neuro2a mouse neuroblastoma cell line using anti-betaIII-tubulin (TU-20; green; 3 ig/ml). Nuclei were stained with DAPI (blue).](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-TU-20-Immunocytochemistry-Immunofluorescence-NB600-1018-img0006.jpg)
![Flow Cytometry: beta-III Tubulin Antibody (TU-20) [NB600-1018] - Analysis of PerCP conjugate of NB600-1018. An intracellular stain was performed on SH-SY5Y cells with beta-III Tubulin (TU-20) antibody NB600-1018PCP (blue) and a matched isotype control NBP2-27287PCP (orange). Cells were fixed with 4% PFA and then permea](http://images.novusbio.com/fullsize/beta-III-Tubulin-Antibody-TU-20-Flow-Cytometry-NB600-1018-img0008.jpg)
![Immunoprecipitation: TRF-2 Antibody [NB100-56694] - Analysis of TRF-2 in HL60 cells. Lane 1. IP (mouse anti-TRF2). Lane 2. IP with control mouse IgG. Lane 3 IP with goat anti-TRF2. Lane 4. IP with pre-immune goat Ig. Lanes 1-4. WB. TRF2 is detected as a ~ 66 kD protein.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Immunoprecipitation-NB100-56694-img0006.jpg "Immunoprecipitation: TRF-2 Antibody [NB100-56694] - Analysis of TRF-2 in HL60 cells. Lane 1. IP (mouse anti-TRF2). Lane 2. IP with control mouse IgG. Lane 3 IP with goat anti-TRF2. Lane 4. IP with pre-immune goat Ig. Lanes 1-4. WB. TRF2 is detected as a ~ 66 kD protein.")
![Immunohistochemistry-Paraffin: TRF-2 Antibody [NB100-56694] - Analysis of Human Tonsil using TRF-2 antibody.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Immunohistochemistry-Paraffin-NB100-56694-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TRF-2 Antibody [NB100-56694] - U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF-2 (shTRF2) and selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF-2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Knockdown-Validated-NB100-56694-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF-2 (shTRF2) and selected with puromycin +/- Dox for a week. One week post selection, +Dox cells were infected with HHV-6A for 48h and processed for IFA using anti-TRF-2 (green) and anti-IE2 (red). Cells with IE2 in punctate form and cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TRF-2-Antibody-Knockdown-Validated-NB100-56694-img0008.jpg)
![Western Blot: TRF-2 Antibody [NB100-56694] - TRF2 knockdown affect HHV-6A/B chromosomal integration.A) U2OS cells were transduced with lentiviral vectors expressing a scrambles shRNA (shCtrl) or a shTRF2. After a week of selection, cells were monitored for TRF2 expression by western blot. B) After a week of selection, shCtrl & shTRF2 treated cells were infected with HHV-6A or HHV-6B. After 30 days, DNA was isolated & the relative frequency of integration, relative to shCtrl set at 100%, estimated by ddPCR. *p<0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415345328.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - TRF2 expression in HHV-6A-infected U2OS cells.U2OS cells were infected with HHV-6A & analyzed for TRF2 & IE2 expression at 24h, 48h & 72h post-infection by dual color immunofluorescence. A) Representative immunofluorescence of TRF2 & IE2 expression in bystander & IE2 expressing cells at 24, 48h & 72h post infection. B) Mean relative TRF2 expression ± SD in uninfected (blue), IE2- (green-uninfected bystander) or IE2+ (red-infected) cells at 24h, 48h & 72h post infection. Each symbol represents the relative TRF2 expression from a single nucleus. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415304273.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Binding of TRF2 to viral DNA during HHV-6A/B infection.A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected & HHV-6A-infected HSB-2 cells (B-D) or uninfected & HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C & E) Eluted DNA was hybridized with 32P-labeled Alu, telomeric (TTAGGG)3 or HHV-6A (DR6) probes. After hybridization the membranes were washed & exposed to X-ray films. D & F) Densitometric analysis of relative binding of TRF2 to telomeric & viral DNA. Results of one experiment representative of three are presented & are expressed as signal after normalization to input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-3102024155376.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - TRF2 is required for IE2 localization with telomeres.U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF2 (shTRF2) & selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. B) One week post selection, +Dox cells were infected with HHV-6A for 48h & processed for IFA using anti-TRF2 (green) & anti-IE2 (red). Cells with IE2 in punctate form & cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. C) The percentage of HHV-6A infected cells (from B) was estimated after counting a minimum of 700 cells & scoring the IE2+ ones. Results are expressed as mean %IE2+ cells ± SD. D) Mean percentage ± SD of IE2 localizing with telomeres in the presence (shCtrl +Dox) & absence (shTRF2 +Dox) of TRF2. Each dot represents the % of IE2 foci localizing with telomeres in one nucleus. ****p<0.0001. E) IF-FISH confocal images of shCtrl (+Dox) & shTRF2 (+Dox) cells analyzed for TRF2 (green), IE2 (red) & telomeres (cyan). Nuclei are outlined by dashed circles. Examples of IE2 localizing with telomeres (top row) or not found with telomeres (bottom row) are highlighted by the dashed polygons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-31020241612657.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Binding of TRF2 to viral DNA during HHV-6A/B infection.A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected & HHV-6A-infected HSB-2 cells (B-D) or uninfected & HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C & E) Eluted DNA was hybridized with 32P-labeled Alu, telomeric (TTAGGG)3 or HHV-6A (DR6) probes. After hybridization the membranes were washed & exposed to X-ray films. D & F) Densitometric analysis of relative binding of TRF2 to telomeric & viral DNA. Results of one experiment representative of three are presented & are expressed as signal after normalization to input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415523926.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - A) A stick diagram of the IE2 protein with various domains identified is presented. B) Colocalization of HHV-6A IE2 protein with telomeres in the absence of viral DNA. U2OS cells were transfected with an empty vector, with IE2 expression vector or with IE2 delta 1290–1500 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. Telomeres were labeled in cyan & IE2 in red. Nuclei are outlined by dashed lines. Examples of IE2 colocalizing with telomeres are presented in a 3D view (white arrows). C) The graph represents the mean ± SD % of WT IE2 & delta 1290–1500 IE2 localizing with telomeres. D) Lack of colocalization between HHV-6A p41 & telomeres in uninfected cells. U2OS cells were transfected with an empty vector or with a p41 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. TRF2 was labeled green, p41 in red & nuclei outlined by a dashed line. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-310202415541930.jpg)
![Immunocytochemistry/ Immunofluorescence: TRF-2 Antibody [NB100-56694] - Colocalization of shelterin complex proteins & HHV-6A IE2 protein at VRC & cellular telomeres.A) U2OS cells were mock-infected or infected with HHV-6A for 48h after which cells were processed for IF-FISH. Telomeres were labeled in magenta, TRF2 in green & IE2 in red. The panels in the middle row show images of cells with IE2 patches overlapping with large, diffuse TRF2 & telomeric staining (rectangles). The panels in the third row represent infected cells with punctate IE2 pattern colocalizing with TRF2 & telomeres (dashed squares). The colocalization of IE2, TRF2 & telomeres are shown in both 2D & 3D images. B) Uninfected & HHV-6A-infected U2OS cells were transfected with an empty vector, a myc-tagged-TRF1 expression vector. Forty-eight hours later cells were processed for IF-FISH. TRF1 was labeled in green & IE2 in red. Nuclei were stained with DAPI. Images on the far right show 2D colocalization of TRF1 with IE2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32320442), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56694_goat-polyclonal-trf-2-antibody-31020241612621.jpg)
![Western Blot: FGFR1OP Antibody (2B1) [H00011116-M01] - Analysis of FGFR1OP expression in transfected 293T cell line by FGFR1OP monoclonal antibody (M01), clone 2B1. Lane 1: FGFR1OP transfected lysate(43.1 KDa). Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/FGFR1OP-Antibody-2B1-Western-Blot-H00011116-M01-img0006.jpg "Western Blot: FGFR1OP Antibody (2B1) [H00011116-M01] - Analysis of FGFR1OP expression in transfected 293T cell line by FGFR1OP monoclonal antibody (M01), clone 2B1. Lane 1: FGFR1OP transfected lysate(43.1 KDa). Lane 2: Non-transfected lysate.")
![Immunocytochemistry/Immunofluorescence: FGFR1OP Antibody (2B1) [H00011116-M01] - Analysis of monoclonal antibody to FGFR1OP on HeLa cell. Antibody concentration 10 ug/mL.](http://images.novusbio.com/fullsize/FGFR1OP-Antibody-2B1-Immunocytochemistry-Immunofluorescence-H00011116-M01-img0004.jpg)
![Immunohistochemistry-Frozen: FGFR1OP Antibody (2B1) [H00011116-M01] - Rabbit frozen 4% paraformalehyde fixed brain sections. Double labeling with FGFR1OP (Basal bodies in green) and GT335 (cilia in red) antibodies of ependymal whole mount from brain of rabbit kit. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FGFR1OP-Antibody-2B1-Immunohistochemistry-Frozen-H00011116-M01-img0009.jpg)
![ELISA: FGFR1OP Antibody (2B1) [H00011116-M01] - Detection limit for recombinant GST tagged FGFR1OP is approximately 0.03 ng/mL as a capture antibody.](http://images.novusbio.com/fullsize/FGFR1OP-Antibody-2B1-ELISA-H00011116-M01-img0007.jpg)
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western blot analysis of KRAS expression in lysates from human lung cancer cell lines: H23, H358, A549, and H441. Image from verified customer review.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0004.jpg "Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western blot analysis of KRAS expression in lysates from human lung cancer cell lines: H23, H358, A549, and H441. Image from verified customer review.")
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western Blot analysis of KRAS expression in transfected 293T cell line by KRAS monoclonal antibody (M01), clone 3B10-2F2.Lane 1: KRAS transfected lysate(21 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: KRAS Antibody (3B10-2F2) [H00003845-M01] - Analysis of monoclonal antibody to KRAS on HeLa cell. Antibody concentration 10 ug/ml.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Immunocytochemistry-Immunofluorescence-H00003845-M01-img0006.jpg)
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - KRAS monoclonal antibody (M01), clone 3B10-2F2 Analysis of KRAS expression in HeLa.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0008.jpg)
![Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - miRNA-768-3p specifically targets K-ras. Effect of miRNA inhibitors that were reduced by co-culture on the level of pan-RAS, phospho-B-Raf and CD44 and pan-Akt by western blotting. Also shown is the effect of different miRNA inhibitors on the level of K-ras in H520 cells by western blot. Cropped blots are shown and were run under the same experimental conditions. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep02392), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-Western-Blot-H00003845-M01-img0011.jpg)
![ELISA: KRAS Antibody (3B10-2F2) [H00003845-M01] - Detection limit for recombinant GST tagged KRAS is approximately 1ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/KRAS-Antibody-3B10-2F2-ELISA-H00003845-M01-img0010.jpg)
![Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0076.jpg "Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: p53 Antibody [NB200-171] - FFPE section of human lung cancer Antibody: Affinity purified rabbit anti- p53 used at 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p53-Antibody-Immunohistochemistry-Paraffin-NB200-171-img0075.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - p53 in Jurkat Cells, fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 million cells were stained with 1.5 ug anti-KLH IgG control or anti-p53 NB200-171 and secondary FITC-conjugated goat anti-rabbit (in a 150ul reaction). Black- anti-KLH control IgG; Red- anti-HDMX.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0002.jpg)
![Chromatin Immunoprecipitation Sequencing: p53 Antibody [NB200-171] - Chromatin from MCF7 was immunoprecipitated with anti-p53 antibody and analyzed by DNA sequencing. The figure illustrates the peak distribution of p53 binding within a 250 Kb region of chromosome 6 as detected using anti-p53. ChIP-seq validation performed by Active Motif, Carlsbad, CA.](http://images.novusbio.com/fullsize/p53-Antibody-Chromatin-Immunoprecipitation-Sequencing-NB200-171-img0073.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (100 ug) from 293T cells that were treated with an siRNA for p53 (+) or mock treated (-). Antibody used at the indicated concentrations.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0003.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - Baseline p53 expression in human lymphocytes. Image from verified customer review.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0004.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: p53 Antibody [NB200-171] - Detection of human P53 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-P53 antibody NB200-171 used for IP at 3 ug per reaction. P53 was also immunoprecipitated by rabbit anti-P53 antibody NB100-2204. For blotting immunoprecipitated P53, NB200-171 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Immunoprecipitation-NB200-171-img0077.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining in human skin and pancreas tissues. Corresponding KLF4 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0021.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining in human skin and pancreas tissues. Corresponding KLF4 RNA-seq data are presented for the same tissues.")
![Immunocytochemistry/Immunofluorescence: KLF4 Antibody [NBP1-83940] - Staining of human cell line A-431 shows localization to nucleoplasm. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-83940-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: KLF4 Antibody [NBP1-83940] - Human breast cancer cell MCF-7 was treated with carboplatin, alone or in combination with Stat3 inhibitor, for 72 hours, and the expression of Klf4 was detected by Western blot. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP1-83940-img0022.jpg)
![Western Blot: KLF4 Antibody [NBP1-83940] - Analysis in control (vector only transfected HEK293T lysate) and KLF4 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP1-83940-img0023.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: KLF4 Antibody [NBP1-83940] - MDA-MB-231 subclones transfected with NTC or HIF-1 alpha shRNA vector were treated with vehicle (V) or paclitaxel (P) and immunoblot assay was performed. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP1-83940-img0024.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human colon shows moderate to strong nuclear positivity in glandular cells.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0017.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human pancreas shows no positivity in exocrine glandular cells as expected.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0018.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human skin shows moderate to strong nuclear positivity in keratinocytes.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0019.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human testis shows moderate to strong nuclear positivity in a subset of cells in seminiferous ducts.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0020.jpg)
![Western Blot: KLF4 Antibody [NBP1-83940] - HIFs are required for hypoxia-induced expression of pluripotency factorsA-C. Breast cancer cell lines were exposed to 20% or 1% O2 for 24 h & NANOG (A), KLF4 (B), & SOX2 (C) mRNA levels were determined by RT-qPCR, relative to 18S rRNA, & normalized to the mean value for MDA-MB-231 cells (MDA231) at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. same cell line at 20% O2 by Student's t test. D & E. HCC-1954 (D) & MCF-7 (E) subclones, which were stably transfected with an expression vector encoding a non-targeting control (NTC) shRNA, or vector encoding shRNA targeting HIF-1 alpha (sh1 alpha ) or HIF-2 alpha (sh2 alpha ), or vectors encoding shRNAs targeting both HIF-1 alpha & HIF-2 alpha (DKD), were exposed to 20% or 1% O2 for 24 h & RT-qPCR was performed to determine NANOG (D) or KLF4 (E) mRNA levels relative to 18S rRNA. The results were normalized to NTC at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC at 20% O2; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. NTC at 1% O2 by ANOVA. F. ZR75.1 cells treated with vehicle or digoxin (200 nM) were exposed to 20% or 1% O2 for 24 h & SOX2 mRNA was measured (mean ± SEM; n = 3). *P < 0.05, **P < 0.01 vs. NTC at 20% O2; ###P < 0.001 vs. NTC at 1% O2 by ANOVA. G & H. NTC & DKD subclones of HCC-1954 (G) & MCF-7 (H) were exposed to 20% or 1% O2 for 48 h, whole cell lysates were prepared, & immunoblot assays were performed to analyze HIF-1 alpha , HIF-2 alpha , NANOG & KLF4 protein expression. Actin was also analyzed as a loading control. I. ZR75.1 cells were treated with vehicle or digoxin (200 nM), exposed to 20% or 1% O2 for 48 h, & HIF-1 alpha , NANOG & SOX2 immunoblot assays were performed. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11743), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-83940_rabbit-polyclonal-klf4-antibody-310202416121929.jpg)
![Western Blot: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of 25 ug of PC12 cell lysates.](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Western-Blot-NB300-526-img0018.jpg "Western Blot: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of 25 ug of PC12 cell lysates.")
![Immunocytochemistry/Immunofluorescence: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 (green) showing positive staining in the secretion of Hela cells (right) compared with a negative control in the absence of primary antibody (left).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunocytochemistry-Immunofluorescence-NB300-526-img0015.jpg)
![Immunohistochemistry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Immunolocalization of ET-1 in human bowel.](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunohistochemistry-NB300-526-img0017.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in 3T3 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 (green) showing positive staining in the secretion of PC12 cells (right) compared with a negative control in the absence of primary antibody (left).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunocytochemistry-Immunofluorescence-NB300-526-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 (green) showing positive staining in the secretion of HUVEC cells (right) compared with a negative control in the absence of primary antibody (left).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunocytochemistry-Immunofluorescence-NB300-526-img0014.jpg)
![Immunohistochemistry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Immunolocalization of ET-1 in human bowel.](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunohistochemistry-NB300-526-img0016.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in HepG2 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0006.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in 293T cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0007.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in HepG2 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0011.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0010.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - p53 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using a 1 ug/mL mouse anti-p53 monoclonal (NBP2-29453, Novus Biologicals) for 1 hour at room temperature followed by the appropriate HRP polymer reagent, anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0008.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Analysis of p53 1) A431 2) MCF7 and 3) HEK293 lysate probed with p53 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0001.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - Formalin-paraffin human colon carcinoma stained with p53 Ab (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0003.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Simple Western lane view shows a specific band for p53 in 0.2 mg/ml of MDA-MB-231 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0004.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Electropherogram image of the corresponding Simple western lane view. p53 antibody was used at 10 ug/ml dilution on MDA-MB-231 lysate(s) respectively.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0005.jpg)
![Western Blot: PARD3/Par3 Antibody [NBP1-88861] - Analysis in human cell lines A-549 and U-251MG. Corresponding RNA-seq data are presented for the same cell lines. Loading control: Anti-GAPDH.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Western-Blot-NBP1-88861-img0017.jpg "<b>Orthogonal Strategies Validation. </b>Western Blot: PARD3/Par3 Antibody [NBP1-88861] - Analysis in human cell lines A-549 and U-251MG. Corresponding RNA-seq data are presented for the same cell lines. Loading control: Anti-GAPDH.")
![<b>Orthogonal Strategies Validation. </b>Simple Western: PARD3/Par3 Antibody [NBP1-88861] - Simple Western lane view shows a specific band for PARD3/Par3 in 0.2 mg/ml of RT-4 lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Simple-Western-NBP1-88861-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - Staining of human cell line U-2 OS shows localization to cell junctions. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - Staining PARD3 in mouse trophoblast stem cells. Verified customer review from 1DegreeBio.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0012.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human colon shows distinct luminal membranous positivity in glandular cells.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - MCAM is required to establish cell autonomous polarity. In wild-type myotubes PAR3 remains cytoplasmic. MCAM contributes to the establishment of cell autonomous polarity in myogenic and chondrogenic differentiation. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28923978/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0023.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human skin shows weak to moderate cytoplasmic positivity in epidermal cells.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - Staining of human cell line 8505C cells (anaplastic thyroid cancer cell line). Image from verified customer review.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0013.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human kidney shows weak to moderate membranous positivity in cells in tubules.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0019.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human cerebellum shows moderate positivity in neuropil.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0020.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human fallopian tube shows weak to moderate positivity in luminal membrane in glandular cells.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0021.jpg)
![Simple Western: PARD3/Par3 Antibody [NBP1-88861] - Electropherogram image(s) of corresponding Simple Western lane view. PARD3/Par3 antibody was used at 1:100 dilution on RT-4 lysate(s).](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Simple-Western-NBP1-88861-img0015.jpg)
![Immunocytochemistry/ Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - MCAM is required to establish cell autonomous polarity. (A) In elongating myotubes (10T1/2 cells treated with testosterone for 7 days) VANGL2 is localized asymmetrically at the tip of the cell. (B) The VANGL2 enriched tip of the cell is marked by MSN. (C) In MCAM knockout C164 cells myotube elongation fails, MSN labels the whole plasma membrane & VANGL2 is spread across the cytoplasm. (D) Highly polarized localization of MCAM & SCRIB at the distal end of growing wild-type myotube. Separate channels of the boxed area are shown on the right. (E) In MCAM knockout cells SCRIB levels remain low & it is spread evenly in the cell. (F) In wild-type myotubes PAR3 remains cytoplasmic, whereas (G) in MCAM knockout C164 cells it can be detected at the cell cortex. (H) RT-qPCR demonstrates reduced expression of Scrib in MCAM mutant cell lines. Cells were treated for 7 days with BMP2 or testosterone (n=3; **P<0.01; ***P<0.001; two-tailed t-test; mean±s.e.m.). (I) Deletion of MCAM endocytosis motif leads to similar polarity defects as complete MCAM elimination. VANGL2 is evenly spread in U125 cells & PAR3 accumulates in cell cortex. (J) In chondrogenic differentiation VANGL2 was observed asymmetrically in limited number of cells. In MCAM mutant cell lines (C149, C164, U125) VANGL2 accumulated around the nucleus. (K) Initiation of myogenic (4-day culture with testosterone) & chondrogenic differentiation (4-day culture with BMP2) led to downregulation of ERK1/2 phosphorylation (p-ERK1/2). Instead in MCAM mutant cell lines ERK1/2 phosphorylation increased. Scale bars: 25 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/doi/10.1242/bio.027771/256759/MCAM-contributes-to-the-establishment-of-cell), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88861_rabbit-polyclonal-pard3-par3-antibody-310202416113535.jpg)
![Immunocytochemistry/ Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - MCAM is required to establish cell autonomous polarity. (A) In elongating myotubes (10T1/2 cells treated with testosterone for 7 days) VANGL2 is localized asymmetrically at the tip of the cell. (B) The VANGL2 enriched tip of the cell is marked by MSN. (C) In MCAM knockout C164 cells myotube elongation fails, MSN labels the whole plasma membrane & VANGL2 is spread across the cytoplasm. (D) Highly polarized localization of MCAM & SCRIB at the distal end of growing wild-type myotube. Separate channels of the boxed area are shown on the right. (E) In MCAM knockout cells SCRIB levels remain low & it is spread evenly in the cell. (F) In wild-type myotubes PAR3 remains cytoplasmic, whereas (G) in MCAM knockout C164 cells it can be detected at the cell cortex. (H) RT-qPCR demonstrates reduced expression of Scrib in MCAM mutant cell lines. Cells were treated for 7 days with BMP2 or testosterone (n=3; **P<0.01; ***P<0.001; two-tailed t-test; mean±s.e.m.). (I) Deletion of MCAM endocytosis motif leads to similar polarity defects as complete MCAM elimination. VANGL2 is evenly spread in U125 cells & PAR3 accumulates in cell cortex. (J) In chondrogenic differentiation VANGL2 was observed asymmetrically in limited number of cells. In MCAM mutant cell lines (C149, C164, U125) VANGL2 accumulated around the nucleus. (K) Initiation of myogenic (4-day culture with testosterone) & chondrogenic differentiation (4-day culture with BMP2) led to downregulation of ERK1/2 phosphorylation (p-ERK1/2). Instead in MCAM mutant cell lines ERK1/2 phosphorylation increased. Scale bars: 25 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/doi/10.1242/bio.027771/256759/MCAM-contributes-to-the-establishment-of-cell), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88861_rabbit-polyclonal-pard3-par3-antibody-310202416113539.jpg)